[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 19 of about 19
1. Kramer CK, Ferreira N, Silveiro SP, Gross JL, Dora JM, Azevedo MJ: Pituitary gland metastasis from renal cell carcinoma presented as a non-functioning macroadenoma. Arq Bras Endocrinol Metabol; 2010;54(5):498-501
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary gland metastasis from renal cell carcinoma presented as a non-functioning macroadenoma.
  • Metastatic tumors involving the pituitary gland are an uncommon finding and occur in up to 1% of all pituitary tumor resections.
  • Five years ago, he underwent a right radical nephrectomy for renal cell carcinoma, followed by chemotherapy and radiotherapy for lung and parotid metastases.
  • This case illustrates that metastatic pituitary lesions can mimic typical symptoms and signs of pituitary macroadenoma.
  • Furthermore, clinical diabetes insipidus, a common finding of pituitary metastases, can be absent.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Pituitary Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20694412.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


2. Qureshi A, Kalu E, Ramanathan G, Bano G, Croucher C, Panahloo A: IVF/ICSI in a woman with active acromegaly: successful outcome following treatment with pegvisomant. J Assist Reprod Genet; 2006 Nov-Dec;23(11-12):439-42
Genetic Alliance. consumer health - Acromegaly.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IVF/ICSI in a woman with active acromegaly: successful outcome following treatment with pegvisomant.
  • A 29 year old woman with difficult to control acromegaly and a pituitary macroadenoma responded to pegvisomant therapy and subsequently conceived with her first cycle of in-vitro fertilization and intra-cytoplasmic sperm injection.
  • Pregnancy was complicated by gestational diabetes, pituitary gland enlargement and deteriorating visual fields.
  • This complex case required intricate care by a multi-disciplinary team and is likely to represent the first in many cases of assisted conception on pegvisomant therapy for active acromegaly.
  • [MeSH-major] Acromegaly / drug therapy. Fertilization in Vitro. Human Growth Hormone / analogs & derivatives. Sperm Injections, Intracytoplasmic
  • [MeSH-minor] Adult. Female. Humans. Hypophysectomy. Magnetic Resonance Imaging. Pituitary Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1994 Oct 1;121(7):473-7 [8067644.001]
  • [Cites] N Engl J Med. 1985 May 23;312(21):1364-70 [3887166.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Nov;59(5):941-8 [6434588.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Mar;83(3):727-31 [9506716.001]
  • [Cites] Clin Pharmacokinet. 1995 Mar;28(3):235-69 [7758253.001]
  • [Cites] Neurol Neurochir Pol. 1982 Jul-Aug;16(4):281-6 [6292760.001]
  • [Cites] Horm Res. 2001;55 Suppl 2:27-31 [11684872.001]
  • (PMID = 17131181.001).
  • [ISSN] 1058-0468
  • [Journal-full-title] Journal of assisted reproduction and genetics
  • [ISO-abbreviation] J. Assist. Reprod. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / pegvisomant; 12629-01-5 / Human Growth Hormone
  • [Other-IDs] NLM/ PMC3455095
  •  go-up   go-down


3. Harms E, Siggelkow H, Buchfelder M, Saeger W, Hüfner M: [Macroadenoma of the pituitary gland with moderate hyperprolactinaemia]. Dtsch Med Wochenschr; 2003 Mar 28;128(13):667-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Macroadenoma of the pituitary gland with moderate hyperprolactinaemia].
  • [Transliterated title] Makroadenom der Hypophyse mit mässiger Hyperprolaktinämie.
  • HISTORY AND CLINICAL FINDINGS: A 46-year-old woman was referred to the neurosurgery department for treatment of a macroadenoma of the pituitary.
  • INVESTIGATIONS: The endocrinological work-up revealed a moderately elevated prolactin level of 3133 mU/l (147 ng/ml) with intact pituitary functions.
  • She had no visual impairment and the MRI depicted a pituitary tumor with a maximal diameter of 1.9 cm and both intra- and suprasellar extension.
  • DIAGNOSIS, TREATMENT AND CLINICAL COURSE: The diagnosis of a nonfunctioning macrodenoma with functional hyperprolactinemia was made and a selective transsphenoidal adenomectomy was performed.
  • In the meantime, because of persistent galactorrhea and elevated prolactin levels, treatment with cabergolin 0.5 mg/week was started.
  • A follow-up MRI after 3 months of treatment showed a significant shrinkage of the residual tumor.
  • We therefore suggest a drug treatment trial with dopamine agonists in all macroadenoms with hyperprolactinemia, particularly in those with prolactin levels above 2000 mU/l (100 ng/ml).
  • [MeSH-major] Hyperprolactinemia / surgery. Pituitary Neoplasms / surgery. Prolactinoma / surgery
  • [MeSH-minor] Diagnosis, Differential. Ergolines / therapeutic use. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm, Residual / drug therapy. Pituitary Gland / pathology. Pituitary Gland / surgery. Postoperative Complications / drug therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12660899.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ergolines; LL60K9J05T / cabergoline
  •  go-up   go-down


Advertisement
4. Del Monte P, Bernasconi D, Ruelle A, Marugo A, Marugo M, Torre R: [Effect of long-term treatment with octreotide-lar in a TSH-secreting pituitary macroadenoma and secondary hyperthyroidism]. Minerva Endocrinol; 2005 Jun;30(2):95-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of long-term treatment with octreotide-lar in a TSH-secreting pituitary macroadenoma and secondary hyperthyroidism].
  • [Transliterated title] Effetto del trattamento a lungo termine con octreotide-Lar in un caso di macroadenoma ipofisario TSH-secernente.
  • Thyroid autoimmunity tests were negative and ultrasonography evidenced a diffusely enlarged gland.
  • Magnetic resonance (MR) imaging of the pituitary showed a macroadenoma.
  • The patient underwent transphenoidal adenomectomy, and immunohistochemistry confirmed the diagnosis of a TSH-secreting pituitary macroadenoma.
  • The patient was treated with octreotide-Lar (20 mg/monthly), which normalized FT3, FT4 and TSH levels already after 3 months of therapy.
  • This effect is still maintained at 42 months of treatment.
  • MR imaging showed a reduction in the residual lesion after 18 months (>50% in comparison with postsurgical MR) and a further decrease after 36 months of treatment).
  • This suggests that the antiproliferative effect on the adenomatous cells is progressive and continues over time.
  • This patients did not receive radiotherapy, so this action is entirely due to the medical treatment.
  • No significant side effects developed and the patient's compliance was good.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Hyperthyroidism / drug therapy. Hyperthyroidism / etiology. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy. Thyrotropin / secretion
  • [MeSH-minor] Aged. Humans. Male. Thyroid Hormones / blood. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15988405.001).
  • [ISSN] 0391-1977
  • [Journal-full-title] Minerva endocrinologica
  • [ISO-abbreviation] Minerva Endocrinol.
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Thyroid Hormones; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


5. Eom KS, See-Sung C, Kim JD, Kim JM, Kim TY: Primary hypothyroidism mimicking a pituitary macroadenoma: regression after thyroid hormone replacement therapy. Pediatr Radiol; 2009 Feb;39(2):164-7
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hypothyroidism mimicking a pituitary macroadenoma: regression after thyroid hormone replacement therapy.
  • We report a 9-year-old girl with pituitary hyperplasia due to primary hypothyroidism.
  • She presented with growth arrest, abnormal thyroid function studies, and a pituitary mass on MRI.
  • With thyroxine therapy, the pituitary mass regressed and her symptoms resolved.
  • Primary hypothyroidism should be considered in the differential diagnosis of solid mass lesions of the pituitary gland.
  • [MeSH-major] Hormone Replacement Therapy / methods. Hypothyroidism / diagnosis. Hypothyroidism / drug therapy. Pituitary Neoplasms / diagnosis. Thyroxine / administration & dosage
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Humans. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Radiol. 2009 Apr;39(4):417 [19224203.001]
  • [Cites] Endocr Pract. 2006 Jan-Feb;12(1):29-34 [16524860.001]
  • [Cites] Radiology. 1999 Nov;213(2):383-8 [10551216.001]
  • [Cites] Clin Radiol. 2003 Jan;58(1):20-31 [12565204.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):610-38 [8969971.001]
  • [Cites] Arch Pediatr Adolesc Med. 1996 Jun;150(6):623-8 [8646313.001]
  • [Cites] Pituitary. 2005;8(2):99-103 [16195776.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(20):7329-33 [3118365.001]
  • (PMID = 18815780.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] Q51BO43MG4 / Thyroxine
  •  go-up   go-down


6. Flitsch J, Lüdecke DK, Stahnke N, Wiebel J, Saeger W: Transsphenoidal surgery for pituitary gigantism and galactorrhea in a 3.5 year old child. Pituitary; 2000 May;2(4):261-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transsphenoidal surgery for pituitary gigantism and galactorrhea in a 3.5 year old child.
  • The management of pituitary macroadenomas which lead to gigantism may require multiple therapeutical approaches, including medical treatment, surgery, and radiation therapy.
  • In this case, a 3.5 year old child, the youngest successfully treated by TSS so far, suffered from a GH- and prolactin (PRL) secreting macroadenoma of the pituitary gland.
  • MRI scans revealed a macroadenoma of 2.7 cm diameter.
  • In summary, if primary medical therapy alone is unable to adequately reduce hormone hypersecretion and tumor size in early childhood, TSS is recommended.
  • Thus, radiation therapy may be reserved for surgical failure.
  • [MeSH-major] Galactorrhea / complications. Galactorrhea / surgery. Gigantism / complications. Gigantism / surgery. Pituitary Neoplasms / complications. Pituitary Neoplasms / surgery
  • [MeSH-minor] Bromocriptine / therapeutic use. Child, Preschool. Dopamine Agonists / therapeutic use. Female. Human Growth Hormone / blood. Humans. Magnetic Resonance Imaging. Postoperative Complications. Prolactin / blood. Prolactinoma / complications. Prolactinoma / drug therapy. Prolactinoma / pathology. Prolactinoma / surgery. Sphenoid Bone / surgery

  • Genetic Alliance. consumer health - Gigantism.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1991 Apr;28(4):502-5 [2034342.001]
  • [Cites] Pathol Res Pract. 1991 Jun;187(5):574-6 [1923951.001]
  • [Cites] Acta Oncol. 1998;37(1):97-9 [9572661.001]
  • [Cites] Neurosurgery. 1996 Sep;39(3):484-92; discussion 492-3 [8875478.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):23-8 [8989226.001]
  • [Cites] Br Med J. 1975 Feb 8;1(5953):299-303 [1111790.001]
  • [Cites] Surg Neurol. 1983 Dec;20(6):498-503 [6648790.001]
  • [Cites] Neurosurgery. 1994 Feb;34(2):207-12; discussion 212 [8177379.001]
  • [Cites] Schweiz Med Wochenschr. 1986 Oct 18;116(42):1431-40 [3024309.001]
  • [Cites] J Neurosurg. 1993 Jul;79(1):70-5 [8315471.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):693-712 [1521519.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Aug;80(8):2475-9 [7629245.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):557-65 [7928486.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3308-14 [9329359.001]
  • [Cites] Prog Exp Tumor Res. 1987;30:362-70 [3628819.001]
  • [Cites] J Neurosurg. 1993 Feb;78(2):205-15 [8421204.001]
  • [Cites] Neuropediatrics. 1992 Oct;23(5):228-34 [1454140.001]
  • [Cites] Metabolism. 1996 Aug;45(8 Suppl 1):72-4 [8769388.001]
  • [Cites] J Neurosurg. 1983 Oct;59(4):590-5 [6886777.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1982 Sep;45(9):780-5 [7131010.001]
  • [Cites] J Clin Endocrinol Metab. 1987 Mar;64(3):447-53 [2880861.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1031-4 [9169809.001]
  • [Cites] J Laryngol Otol. 1983 Oct;97(10 ):917-23 [6619653.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1013-21; discussion 1021-2 [9588545.001]
  • [Cites] Horm Res. 1978;9(4):201-7 [669570.001]
  • [Cites] Arch Dis Child. 1992 Aug;67(8):1039-41 [1520009.001]
  • [Cites] J Clin Endocrinol Metab. 1973 Mar;36(3):531-47 [4119548.001]
  • [Cites] Arch Dis Child. 1997 May;76(5):398-404 [9196353.001]
  • [Cites] Neuropsychologia. 1992 Mar;30(3):257-75 [1574161.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):374-8 [9467544.001]
  • [Cites] Clin Endocrinol (Oxf). 1989 Feb;30(2):131-40 [2612015.001]
  • [Cites] J Craniofac Genet Dev Biol. 1997 Oct-Dec;17(4):190-7 [9493077.001]
  • [Cites] Acta Paediatr Scand. 1985 Sep;74(5):807-14 [4050429.001]
  • [Cites] J Pediatr. 1997 Dec;131(6):905-9 [9427898.001]
  • [Cites] Acta Neurochir Suppl. 1995;63:81-4 [7502734.001]
  • [Cites] Acta Neuropathol. 1993;85(2):167-74 [8382895.001]
  • [Cites] Acta Endocrinol Suppl (Copenh). 1986;279:434-9 [3535340.001]
  • [Cites] Acta Neurochir (Wien). 1989;96(1-2):32-8 [2539000.001]
  • [Cites] Radiat Oncol Investig. 1998;6(1):26-34 [9503487.001]
  • [Cites] Cancer. 1992 Jan 1;69(1):271-5 [1727672.001]
  • [Cites] Br Med J. 1972 Sep 16;3(5828):669-72 [4675488.001]
  • [Cites] J Pediatr. 1992 Jun;120(6):931-4 [1593354.001]
  • [Cites] J Clin Endocrinol Metab. 1980 Mar;50(3):578-85 [6244327.001]
  • [Cites] J Endocrinol Invest. 1981 Oct-Dec;4(4):445-50 [6278015.001]
  • [Cites] Neurosurgery. 1994 Aug;35(2):179-83; discussion 183-4 [7969823.001]
  • [Cites] N Engl J Med. 1994 Sep 8;331(10):629-36 [8052272.001]
  • [Cites] Arch Intern Med. 1991 Aug;151(8):1573-8 [1872661.001]
  • [Cites] J Endocrinol Invest. 1997 Oct;20(9):537-46 [9413808.001]
  • (PMID = 11081147.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists; 12629-01-5 / Human Growth Hormone; 3A64E3G5ZO / Bromocriptine; 9002-62-4 / Prolactin
  •  go-up   go-down


7. Leung G, Tsao SW, Wong YC: The effect of flutamide and tamoxifen on sex hormone-induced mammary carcinogenesis and pituitary adenoma. Breast Cancer Res Treat; 2002 Mar;72(2):153-62
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of flutamide and tamoxifen on sex hormone-induced mammary carcinogenesis and pituitary adenoma.
  • We showed that tamoxifen could totally inhibit mammary carcinogenesis while flutamide cause a delay and reduction in tumour incidence in the 12 months treatment term.
  • Blocking effect of flutamide and tamoxifen on T + E2 (testosterone and 17beta-estradiol) short-terms treatment was demonstrated by the similar histological changes identified in the mammary glands of the T + E2 and drug treated rats to that of the age matched E2 and T controls, respectively.
  • Autopsy of the tumour bearing rats showed presence of pituitary macroadenoma causing compression and atrophy of the brain stem.
  • Tamoxifen was also effective in blocking the formation of pituitary adenoma in the sex hormone treated rats.
  • Pituitary size and level of prolactin were higher in the T + E2 + flutamide group than the T + E2 group in both short-term and long-term treatments.
  • It suggests that testosterone may have a role in counteracting estradiol stimulation on the pituitary lactotropes although it is synergistic to estrogen in mammary carcinogenesis.
  • Pituitary adenomas were found in all rats that developed mammary adenocarcinoma but not vice versa suggesting that prolactin level elevation alone cannot lead to mammary tumorigenesis.
  • The animal model, in addition to mammary carcinogenesis, may be useful for investigation of anti-estrogen therapy in pituitary adenomas.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. Breast / drug effects. Breast Neoplasms / prevention & control. Flutamide / pharmacology. Pituitary Gland / drug effects. Prolactinoma / prevention & control. Tamoxifen / pharmacology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12038706.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Gonadal Steroid Hormones; 094ZI81Y45 / Tamoxifen; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 76W6J0943E / Flutamide
  •  go-up   go-down


8. Ragel BT, Couldwell WT: Pituitary carcinoma: a review of the literature. Neurosurg Focus; 2004 Apr 15;16(4):E7
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary carcinoma: a review of the literature.
  • Pituitary carcinomas, defined as distant metastases of a pituitary neoplasm, are rare; fewer than 140 reports exist in the English literature.
  • The initial presenting pituitary tumor is usually a secreting, invasive macroadenoma, with adrenocorticotropic hormone (ACTH)--and prolactin (PRL)--secreting tumors being the most common.
  • The latency period between the diagnosis of a pituitary tumor and the diagnosis of a pituitary carcinoma is 9.5 years for ACTH-producing lesions and 4.7 years for PRL-secreting tumors.
  • Treatment options include additional surgery, radiotherapy, and chemotherapy, all of which are associated with poor results.
  • Future studies will focus on identifying those invasive pituitary tumors most likely to metastasize and treating them aggressively before they progress to pituitary carcinomas.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / therapy
  • [MeSH-minor] Adrenocorticotropic Hormone / secretion. Biomarkers, Tumor / analysis. Gene Expression Regulation, Neoplastic. Genes, p53. Genes, ras / genetics. Humans. Pituitary Gland / pathology. Pituitary Gland / ultrastructure. Point Mutation. Prolactin / secretion

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurosurg Focus. 2005 Sep 15;19(3):E11; author reply E11 [16196164.001]
  • (PMID = 15191336.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9002-60-2 / Adrenocorticotropic Hormone; 9002-62-4 / Prolactin
  • [Number-of-references] 122
  •  go-up   go-down


9. Chibbaro S, Benvenuti L, Carnesecchi S, Faggionato F, Gagliardi R: An interesting case of a pituitary adenoma apoplexy mimicking an acute meningitis. Case report. J Neurosurg Sci; 2007 Jun;51(2):65-9; discussion 68-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An interesting case of a pituitary adenoma apoplexy mimicking an acute meningitis. Case report.
  • Apoplexy of a pituitary adenoma is a rare and under-diagnosed clinical occurrence.
  • It results from either infarction or haemorrhage into an adenoma of the pituitary gland.
  • A 33-year-old male suffered a pituitary macroadenoma apoplexy, clinically indistinguishable from an infectious meningitis at presentation.
  • Three days after surgery, the patient developed a left ophthalmoplegia due to 3(rd) nerve palsy, which fully resolved within 2 months.
  • In conclusion the authors believe that, despite many reports in the literature, encouraging conservative management in pituitary apoplexy by administering intravenous steroids, surgery should be undertaken in order to avoid eventual visual field defects, relieve pituitary gland compression and prevent a possible recurrent apoplectic episode or tumor re-growth.
  • [MeSH-major] Adenoma / complications. Meningitis / diagnosis. Pituitary Apoplexy / diagnosis. Pituitary Gland / pathology. Pituitary Neoplasms / complications
  • [MeSH-minor] Acute Disease. Adult. Brain Infarction / complications. Brain Infarction / etiology. Brain Infarction / pathology. Diagnosis, Differential. Headache / etiology. Humans. Hydrocortisone / therapeutic use. Hypopituitarism / drug therapy. Hypopituitarism / etiology. Hypopituitarism / pathology. Magnetic Resonance Imaging. Male. Neck Pain / etiology. Neurosurgical Procedures / methods. Oculomotor Nerve Diseases / etiology. Postoperative Complications / etiology. Tomography, X-Ray Computed. Treatment Outcome. Unconsciousness / etiology. Vomiting / etiology

  • MedlinePlus Health Information. consumer health - Meningitis.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571037.001).
  • [ISSN] 0390-5616
  • [Journal-full-title] Journal of neurosurgical sciences
  • [ISO-abbreviation] J Neurosurg Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


10. Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Khandji AG, Post KD: Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors. Pituitary; 2004;7(1):21-30
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors.
  • Dopamine agonists have been used as adjunctive therapy for acromegaly for many years, but relatively few studies have assessed the efficacy of a newer agonist, cabergoline.
  • In order to assess this possibility further, we have evaluated the biochemical response to cabergoline therapy in patients with acromegaly at our center.
  • We describe first an unusual patient who presented with a pituitary macroadenoma secreting both GH and prolactin.
  • Cabergoline therapy alone was highly effective in this patient and normalized his levels of all three hormones and his gonadal function as well as produced significant shrinkage of his pituitary tumor.
  • Mean baseline GH was 1.3 +/- .23 ng/ml and fell to a nadir of 0.85 +/- .18 ng/ml on cabergoline therapy (p = 0.03).
  • Mean baseline IGF-I was 520 +/- 45.2 ng/ml and fell to a mean nadir during cabergoline therapy of 368 +/- 29.8 ng/ml (p = 0.0013).
  • At the completion of the cabergoline therapy study period, however, mean IGF-I was 453 +/- 46 ng/ml, not significantly lower than the baseline value (p = 0.11).
  • No changes in tumor sizes occurred on cabergoline therapy.
  • Eight of 14 patients achieved a normal IGF-I at some point during the 24 weeks study period, but the efficacy of cabergoline waned with time as only 3 of 14 (21%) of patients had a persistently normal IGF-I with up to 18 months of cabergoline therapy.
  • Six patients had modest hyperprolactinemia at diagnosis (26-142 ng/ml) and 5 patients had positive immunohistochemical staining of their tumor for prolactin, but in neither of these small groups was cabergoline therapy more effective at normalizing IGF-I than in those patients with apparently pure GH secreting tumors.
  • Three of 14 patients (21%) had side effects that limited therapy.
  • A trial of cabergoline as adjunctive therapy may be considered in select patients with mild disease and small tumor residuals, but the expectation for biochemical control in these patients needs to be kept low, even for tumors that co-secrete GH and prolactin.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Ergolines / therapeutic use. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Acromegaly / drug therapy. Acromegaly / pathology. Adult. Biomarkers / blood. Human Growth Hormone / secretion. Humans. Insulin-Like Growth Factor I / metabolism. Magnetic Resonance Imaging. Male. Pituitary Gland / pathology. Prolactin / secretion

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1990 Apr 5;322(14):966-77 [2179724.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):3808-16 [9814451.001]
  • [Cites] Eur J Endocrinol. 1998 Nov;139(5):516-21 [9849816.001]
  • [Cites] Endocr Rev. 1992 May;13(2):220-40 [1352243.001]
  • [Cites] Clin Endocrinol (Oxf). 1985 Feb;22(2):209-17 [4039234.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):904-9 [7915824.001]
  • [Cites] Eur J Clin Invest. 1982 Apr;12(2):151-5 [6807686.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Feb;82(2):518-23 [9024247.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3013-8 [12107192.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Dec;80(12):3395-402 [8530571.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Jun;46(6):745-9 [9274706.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10 ):4759-67 [14557452.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Dec;67(6):1195-204 [3142915.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):374-8 [9467544.001]
  • [Cites] Baillieres Clin Endocrinol Metab. 1995 Apr;9(2):243-70 [7625985.001]
  • [Cites] Clin Endocrinol (Oxf). 1988 Nov;29(5):467-76 [2908102.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):713-35 [1355728.001]
  • [Cites] Drugs. 1995 Feb;49(2):255-79 [7729332.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Oct;63(4):941-5 [3745407.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jun;81(6):2338-43 [8964874.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1171-7 [10770982.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Apr;54(4):469-77 [11318782.001]
  • [Cites] J Endocrinol Invest. 1997 Oct;20(9):537-46 [9413808.001]
  • (PMID = 15638294.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK02561
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers; 0 / Ergolines; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; 9002-62-4 / Prolactin; LL60K9J05T / cabergoline
  •  go-up   go-down


11. Dalan R, Leow MK: Pituitary abscess: our experience with a case and a review of the literature. Pituitary; 2008;11(3):299-306
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary abscess: our experience with a case and a review of the literature.
  • Pituitary abscess is a rare disease.
  • Despite recent advances in radiological investigations, making a definitive diagnosis preoperatively remains challenging.
  • Magnetic resonance imaging of the brain revealed a sellar mass with peripheral enhancement that was misdiagnosed as a pituitary macroadenoma.
  • However this patient subsequently lost complete function of the pituitary gland, resulting in central diabetes insipidus and required permanent hormonal replacement therapy in the deficient endocrine axes.
  • [MeSH-major] Abscess / diagnosis. Adenoma / diagnosis. Diagnostic Errors. Pituitary Diseases / diagnosis. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Diabetes Insipidus, Neurogenic / drug therapy. Diabetes Insipidus, Neurogenic / etiology. Drainage. Headache / etiology. Hormone Replacement Therapy. Humans. Hypopituitarism / drug therapy. Hypopituitarism / etiology. Magnetic Resonance Imaging. Male. Middle Aged. Pituitary Function Tests

  • MedlinePlus Health Information. consumer health - Abscess.
  • MedlinePlus Health Information. consumer health - Pituitary Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuroophthalmol. 2005 Sep;25(3):185-8 [16148624.001]
  • [Cites] J Neuroradiol. 1999 Oct;26(3):196-9 [10655674.001]
  • [Cites] Br J Neurosurg. 1997 Apr;11(2):139-43 [9156001.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):81-117, vi [10207686.001]
  • [Cites] Endocr J. 2003 Dec;50(6):825-9 [14709857.001]
  • [Cites] Am J Ophthalmol. 1983 Aug;96(2):200-8 [6881243.001]
  • [Cites] Endocr Pract. 2002 Nov-Dec;8(6):424-8 [15251832.001]
  • [Cites] J Clin Neurosci. 2004 Jun;11(5):533-4 [15177403.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Feb;43(2):100-3 [12627890.001]
  • [Cites] Acta Neurochir (Wien). 2004 May;146(5):521-4 [15118891.001]
  • [Cites] J Clin Neurosci. 2005 Feb;12(2):190-3 [15749430.001]
  • [Cites] J Endocrinol Invest. 2001 Jan;24(1):45-50 [11227732.001]
  • [Cites] J Endocrinol Invest. 2001 Dec;24(11):887-91 [11817714.001]
  • [Cites] J Clin Neurosci. 2006 Dec;13(10):1038-41 [17113986.001]
  • [Cites] J Clin Pathol. 2002 Dec;55(12):965-6 [12461069.001]
  • [Cites] Pituitary. 2006;9(3):267-73 [16845602.001]
  • [Cites] J Clin Neurosci. 2006 Aug;13(7):774-7 [16931019.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):233-41 [11780892.001]
  • [Cites] Neurol Med Chir (Tokyo). 2005 Jun;45(6):327-30 [15973069.001]
  • [Cites] Arq Neuropsiquiatr. 2002 Sep;60(3-B):861-5 [12364963.001]
  • [Cites] J Clin Neurosci. 2007 Mar;14(3):286-8 [17188492.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):335-8 [11213976.001]
  • (PMID = 17594523.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


12. Quintero Wolfe S, Hood B, Barker J, Benveniste RJ: Primary central nervous system lymphoma mimicking pituitary apoplexy: case report. Pituitary; 2009;12(1):76-9
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma mimicking pituitary apoplexy: case report.
  • Lymphoma involving the pituitary gland is very rare and usually results from metastatic spread of systemic lymphoma.
  • We present a case of primary central nervous system (CNS) large B cell lymphoma that manifested as pituitary apoplexy.
  • A 45-year-old woman presented with headache, and then rapidly developed a third nerve palsy and bitemporal hemianopsia.
  • Imaging suggested a pituitary macroadenoma, with spontaneous necrosis, extending into the suprasellar region, compressing the optic chiasm and invading the right cavernous sinus.
  • Chemotherapy with methotrexate, vincristine, procarbazine, and dexamethasone was administered for primary CNS lymphoma.
  • This is an uncommon diagnosis of which the clinician should be aware in order to tailor surgical intervention and provide early institution of proper therapy.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis. Pituitary Apoplexy / pathology

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2007 Sep;107(3):660-5 [17886569.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2461-5 [3179963.001]
  • [Cites] Pituitary. 2008;11(3):307-11 [17899387.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4567-75 [11600505.001]
  • [Cites] Endocr J. 2005 Oct;52(5):543-9 [16284431.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1470-6 [11297569.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):81-117, vi [10207686.001]
  • [Cites] J Neurosurg. 2006 Jun;104(6):931-7 [16776337.001]
  • [Cites] Top Magn Reson Imaging. 2005 Jul;16(4):289-99 [16785844.001]
  • [Cites] Pituitary. 2005;8(2):139-46 [16379034.001]
  • [Cites] Am J Hematol. 2000 Apr;63(4):231-2 [10706771.001]
  • [Cites] Pituitary. 2000 May;2(4):283-7 [11081150.001]
  • [Cites] Ann Intern Med. 1993 Dec 1;119(11):1093-104 [8239229.001]
  • [Cites] Neurosurg Focus. 2006 Nov 15;21(5):E13 [17134115.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Mar;23(3):364-7 [11901000.001]
  • [Cites] Neurosurg Focus. 2006 Nov 15;21(5):E7 [17134123.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):227-31 [15072472.001]
  • (PMID = 18205050.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Chen S, Li M, Lian XL, Zeng ZP, Dai WX, Li F, Yu W, Wang RZ: [Octreotide in the diagnosis and treatment of pituitary thyrotropin-secreting adenoma]. Zhonghua Nei Ke Za Zhi; 2006 Nov;45(11):910-3
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Octreotide in the diagnosis and treatment of pituitary thyrotropin-secreting adenoma].
  • OBJECTIVE: To evaluate the efficacy of octreotide in the diagnosis and treatment of pituitary thyrotropin (TSH)-secreting adenoma.
  • METHODS: A 34-year man presented with central hyperthyroidism and pituitary TSH-secreting macroadenoma was reported. (99 m)Tc-octreotide scan and magnetic resonance imaging were completed to make the location diagnosis of the adenoma.
  • RESULTS: Pituitary TSH-secreting adenoma displayed positive sign in (99 m)Tc-octreotide scan.
  • Antithyroid drug was of no help in depressing thyroid function to normal.
  • However, octreotide treatment could revert thyroid function to normal rapidly.
  • A significant shrinkage of tumor mass from 3.0 cm x 2.0 cm x 2.5 cm to 2.0 cm x 2.0 cm x 1.5 cm was observed and a shrinkage of thyroid gland from III to II also observed.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Octreotide / analogs & derivatives. Octreotide / therapeutic use. Organotechnetium Compounds. Pituitary Neoplasms / drug therapy. Thyrotropin / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313878.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / 99mTc-octreotide; 0 / Antineoplastic Agents, Hormonal; 0 / Organotechnetium Compounds; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


14. Li YN, Tao W, Ren ZY, Su CB, Wang RZ: [Magnetic resonance imaging of pituitary hyperplasia in a child with growth arrest and primary hypothyroidism]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug;23(4):412-4
MedlinePlus Health Information. consumer health - Hypothyroidism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Magnetic resonance imaging of pituitary hyperplasia in a child with growth arrest and primary hypothyroidism].
  • We report a case of pituitary hyperplasia in a child presented with significant growth arrest and laboratory evidence of hypothyroidism.
  • Magnetic resonance imaging (MRI) revealed symmetrical pituitary enlargement seemed to be macroadenoma.
  • After thyroid hormone replacement therapy, the child's height increased and pituitary enlargement regressed.
  • Awareness of MRI appearance of pituitary hyperplasia in children with laboratory evidence of hypothyoidism might avoid misdiagnosis for pituitary tumor, which may also manifest as growth disorder, obviating unnecessary surgery.
  • [MeSH-major] Growth Disorders / etiology. Hypothyroidism / complications. Pituitary Gland / pathology. Thyroid Hormones / therapeutic use
  • [MeSH-minor] Child. Hormone Replacement Therapy. Humans. Hyperplasia / diagnosis. Hyperplasia / drug therapy. Magnetic Resonance Imaging. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Growth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12940091.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Thyroid Hormones
  •  go-up   go-down


15. Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP: Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR. Horm Res; 2004;62(5):227-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
  • BACKGROUND/AIMS: The efficacy of transsphenoidal surgery in the treatment of patients with acromegaly is largely dependent on tumour size.
  • A reduction in pituitary tumour volume by medical therapy might therefore improve subsequent surgical cure rates.
  • This study prospectively determined the effects of the depot somatostatin analogue octreotide LAR on pituitary tumour size, GH and IGF-I levels and clinical symptoms in a cohort of previously untreated patients with acromegaly.
  • Prior to commencing LAR therapy, each patient received 3 injections of subcutaneous octreotide (50, 100 and 200 mug) in a randomized order on separate days, and the serum GH response was measured.
  • Pituitary tumour volume was calculated from MRI or computed tomography scans at baseline, then 3 and 6 months after initiation of treatment, and assessed by a 'blinded' radiologist in random order.
  • At baseline, 4 patients had a macroadenoma and 2 patients had a microadenoma.
  • For the latter, the whole gland volume was measured.
  • Octreotide LAR results in significant shrinkage of pituitary tumours of newly diagnosed patients with acromegaly.
  • [MeSH-major] Acromegaly / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 S. Karger AG, Basel.
  • (PMID = 15477693.001).
  • [ISSN] 0301-0163
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Delayed-Action Preparations; 67763-96-6 / Insulin-Like Growth Factor I; 9002-72-6 / Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


16. Fischli S, Stettler C, Christ E: [A rare cause of cardiogenic shock with psychotic symptoms]. Dtsch Med Wochenschr; 2006 Oct 20;131(42):2333-6
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He was known to have had a macroadenoma of the pituitary gland which had been excised 10 years before.
  • No information about his current medication was available.
  • Several hours after admission the patient developed signs of acute cardiac failure and cardiogenic shock.
  • He was admitted to the intensive care unit, intubated and treated with vasoactive drugs.
  • Later investigations revealed that the patient had stopped his hormonal therapy (hydrocortisone and thyroxine) at least 3 months previously.
  • DIAGNOSIS, THERAPY AND COURSE: The diagnosis of acute pituitary insufficiency with myxedema coma and hypocortisolism was suspected and the patient was treated with parenteral cortisone and L-thyroxine.
  • CONCLUSIONS: Myxedema coma can be a predominant finding of acute anterior pituitary insufficiency.
  • Immediate diagnosis and therapy are crucial to reduce the otherwise high mortality.
  • [MeSH-minor] Adult. Humans. Hydrocortisone / administration & dosage. Hydrocortisone / blood. Hydrocortisone / therapeutic use. Hypophysectomy / adverse effects. Male. Myxedema / complications. Myxedema / diagnosis. Myxedema / drug therapy. Myxedema / etiology. Thyroxine / administration & dosage. Thyroxine / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043983.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] Q51BO43MG4 / Thyroxine; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


17. Casarini AP, Pinto EM, Jallad RS, Giorgi RR, Giannella-Neto D, Bronstein MD: Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest; 2006 Oct;29(9):826-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.
  • SSTR2 and SSTR5 are usually expressed in GH-secreting pituitary tumors, and both SA bind preferentially to SSTR2 and, to a lesser extent, to SSTR5.
  • We herein describe an acromegalic patient who presented impressive tumor shrinkage without hormonal normalization during primary therapy with SA.
  • Subsequently, he underwent pituitary surgery and expression of SSTR in the removed tumor was performed by real time RT-PCR by the 2-deltaCt method, using GAPDH as internal control.
  • The low affinity of LAN and OCT for this SSTR subtype could be compensated by its high expression in this GH-secreting pituitary macroadenoma.
  • [MeSH-major] Acromegaly / drug therapy. Growth Hormone-Secreting Pituitary Adenoma / drug therapy. Human Growth Hormone / blood. Insulin-Like Growth Factor I / analysis. Octreotide / therapeutic use. Peptides, Cyclic / therapeutic use. Receptors, Somatostatin / metabolism. Somatostatin / analogs & derivatives
  • [MeSH-minor] Adult. Gene Expression. Humans. Male. Pituitary Gland / diagnostic imaging. Radiography. Remission Induction / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1856-63 [15613435.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Aug;63(2):168-75 [16060910.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):2976-81 [11443154.001]
  • [Cites] BMC Biotechnol. 2003 Oct 13;3:18 [14552656.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2646-52 [9709926.001]
  • [Cites] Cell Physiol Biochem. 2002;12 (1):31-8 [11914546.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2797-802 [12788890.001]
  • [Cites] J Neuroendocrinol. 2003 Sep;15(9):822-30 [12899676.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Nov;90(11):6156-61 [16091489.001]
  • [Cites] Metabolism. 1996 Aug;45(8 Suppl 1):17-20 [8769372.001]
  • [Cites] Lab Invest. 2005 Aug;85(8):1040-50 [15951835.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):155-60 [12490654.001]
  • [Cites] J Endocrinol. 1997 Oct;155 Suppl 1:S3-6; discussion S7-8 [9389989.001]
  • [Cites] Life Sci. 1995;57(13):1249-65 [7674817.001]
  • [Cites] Metabolism. 1996 Aug;45(8 Suppl 1):63-4 [8769385.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):781-92 [10690891.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):526-9 [10690849.001]
  • [Cites] Mol Endocrinol. 1997 Oct;11(11):1709-17 [9328352.001]
  • [Cites] Endocrinology. 1994 Dec;135(6):2814-7 [7988476.001]
  • [Cites] Front Neuroendocrinol. 1999 Jul;20(3):157-98 [10433861.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4239-45 [12970293.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):171-90 [10207690.001]
  • [Cites] Mol Endocrinol. 1996 Dec;10(12):1688-96 [8961277.001]
  • [Cites] Clin Invest Med. 1996 Aug;19(4):259-70 [8853574.001]
  • (PMID = 17114915.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Peptides, Cyclic; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 3; 0G3DE8943Y / lanreotide; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I; RWM8CCW8GP / Octreotide
  •  go-up   go-down


18. Leslie H, Courtney CH, Bell PM, Hadden DR, McCance DR, Ellis PK, Sheridan B, Atkinson AB: Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab; 2001 Jun;86(6):2743-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The predominant form is little PRL (molecular mass 23 kDa) with smaller amounts of big PRL (molecular mass 50--60 kDa) and at times big big or macroprolactin (molecular mass 150--170 kDa).
  • All had pituitary imaging, and four had a microadenoma with none having a macroadenoma.
  • [MeSH-minor] Adult. Bromocriptine / therapeutic use. Cohort Studies. Ergolines / therapeutic use. Female. Fertility. Headache / blood. Humans. Magnetic Resonance Imaging. Medical Records. Menstruation. Menstruation Disturbances / blood. Menstruation Disturbances / drug therapy. Middle Aged. Pituitary Gland / pathology. Pituitary Gland / radiography. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Endocrinol Metab. 2002 Apr;87(4):1909-10; author reply 1910 [11932344.001]
  • (PMID = 11397880.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ergolines; 0 / prolactin, polymeric; 30IQX730WE / Polyethylene Glycols; 3A64E3G5ZO / Bromocriptine; 9002-62-4 / Prolactin; LL60K9J05T / cabergoline
  •  go-up   go-down


19. Erer S, Yilmazlar S, Zarifoglu M, Guclu M: A case report on pituitary macroadenoma presented as hemichorea hemiballism syndrome. Neurol Sci; 2008 Sep;29(4):289-90
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report on pituitary macroadenoma presented as hemichorea hemiballism syndrome.
  • [MeSH-major] Adenoma / complications. Adenoma / pathology. Chorea / etiology. Dyskinesias / etiology. Pituitary Neoplasms / complications. Pituitary Neoplasms / pathology
  • [MeSH-minor] Acromegaly / complications. Acute Disease. Adult. Antipsychotic Agents / therapeutic use. Basal Ganglia / pathology. Basal Ganglia / physiopathology. Brain Ischemia / complications. Brain Ischemia / etiology. Brain Ischemia / physiopathology. Diabetes Complications / pathology. Diabetes Complications / physiopathology. Diabetic Ketoacidosis / complications. Diabetic Ketoacidosis / pathology. Diabetic Ketoacidosis / physiopathology. Dibenzothiazepines / therapeutic use. Female. Growth Hormone / metabolism. Growth Hormone / secretion. Humans. Hyperglycemia / complications. Hyperglycemia / drug therapy. Hyperglycemia / physiopathology. Insulin / therapeutic use. Magnetic Resonance Imaging. Pituitary Gland / pathology. Pituitary Gland / physiopathology. Quetiapine Fumarate. Syndrome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Sci. 2002 Aug 15;200(1-2):57-62 [12127677.001]
  • [Cites] J Neurol. 2004 Dec;251(12 ):1486-90 [15645348.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Jan;26(1):194; author reply 194-5 [15661727.001]
  • [Cites] Neurol India. 1999 Mar;47(1):40-2 [10339706.001]
  • [Cites] J Magn Reson Imaging. 2006 Apr;23(4):564-8 [16514597.001]
  • [Cites] Mov Disord. 2006 Nov;21(11):2023-5 [16986158.001]
  • [Cites] J Comput Assist Tomogr. 2002 Nov-Dec;26(6):905-11 [12488734.001]
  • (PMID = 18810608.001).
  • [ISSN] 1590-1874
  • [Journal-full-title] Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  • [ISO-abbreviation] Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Dibenzothiazepines; 0 / Insulin; 2S3PL1B6UJ / Quetiapine Fumarate; 9002-72-6 / Growth Hormone
  •  go-up   go-down






Advertisement